O uso do cannabidiol no tratamento e manejo da dor
DOI:
https://doi.org/10.34119/bjhrv7n2-255Keywords:
cannabidiol, cannabis, dorAbstract
O cannabidiol, composto já conhecido por milhares de anos, tem sido amplamente estudado atualmente para o manejo de diversas condições de saúde, dentre elas a dor. Considerando-se a relevância do assunto em questão até os dias atuais, o objetivo da presente revisão foi analisar uso de cannabidiol para o tratamento e manejo da dor, levando em consideração sua ação no corpo humano e seus potenciais benefícios e malefícios. Para a elaboração do estudo, foram feitas pesquisas em bases de dados, selecionando-se inicialmente 58 artigos, dos quais 23 se enquadraram para a relevância da pesquisa. Apesar de os pesquisadores ainda não compreenderem completamente os exatos mecanismos de ação do composto para o manejo e alívio da dor, pesquisas tem mostrado resultados positivos nos pacientes, principalmente quando utilizadas com outros medicamentos, no entanto, a sociedade ainda necessita de mais pesquisas acerca do tema para uma melhor forma de abordagem e melhor entendimento do assunto.
References
GUIDA, J. et al. Cannabis medicinal como recurso terapéutico: estudio preliminar. Revista Médica del Uruguay, v. 35, n. 4, p. 1-12, 2019.
LUKHELE, S.; MOTADI, L. Cannabidiol rather than Cannabis sativa extracts inhibit cell growth and induce apoptosis in cervical cancer cells. BMC Complement Altern Med, v. 16, n. 1, p. 335-351, 2016.
LÓPEZ-VALERO, I. et al. Optimization of a preclinical therapy of cannabinoids in combination with temozolomide against glioma. Biochemical Pharmacology, n. 157, p. 275-284, 2018a.
LÓPEZ-VALERO, I. et al. Targeting glioma initiating cells with a combined therapy of cannabinoids and temozolomide. Biochemical Pharmacology, n. 157, p. 266-274, 2018b.
KENYON, J.; LIU, W.; DALGLEISH, A. Report of objective clinical responses of cancer patients to pharmaceutical-grade synthetic cannabidiol. Anticancer Research, v. 38 n. 10, p. 5831-5835, 2018.
APARICIO-BLANCO, J. et al. Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters. European Journal of Pharmaceutics and Biopharmaceutics, v. 134, n. 1, p. 126-137, 2019.
SULTAN, A.; MARIE, M.; SHEWEITA, S. Novel mechanism of cannabidiol-induced apoptosis in breast cancer cell lines. The Breast, n. 41, p. 34-41, 2018.
ZHANG, X. et al. Cannabidiol induces cell cycle arrest and cell apoptosis in human gastric cancer SGC-7901 cells. Biomolecules, v. 9, n. 8, p. 302-318, 2019.
AMIN, M. R.; ALI, D. W. Pharmacology of Medical Cannabis. Advances in Experimental Medicine and Biology, v. 1162, n. 1, p. 151–165, 2019.
BORGELT, L. M. et al. The Pharmacologic and Clinical Effects of Medical Cannabis. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, v. 33, n. 2, p. 195–209, fev. 2013.
BLAKE, D. R. et al. Preliminary assessment of the efficacy, tolerability and safety of a cannabis-based medicine (Sativex) in the treatment of pain caused by rheumatoid arthritis. Rheumatology, v. 45, n. 1, p. 50–52, 9 nov. 2005.
NURMIKKO, T. J. et al. Sativex successfully treats neuropathic pain characterised by allodynia: A randomised, double-blind, placebo-controlled clinical trial. Pain, v. 133, n. 1, p. 210–220, dez. 2007.
BUGGY, D. J. et al. Lack of analgesic efficacy of oral δ-9-tetrahydrocannabinol in postoperative pain. Pain, v. 106, n. 1, p. 169–172, nov. 2003.
BEAULIEU, P. Effects of nabilone, a synthetic cannabinoid, on postoperative pain. Canadian Journal of Anesthesia/Journal canadien d’anesthésie, v. 53, n. 8, p. 769–775, ago. 2006.
HILL, K. P.; PALASTRO, M. D. Medical cannabis for the treatment of chronic pain and other disorders: misconceptions and facts. Polish Archives of Internal Medicine, 25 out. 2017.
MARTÍN-SÁNCHEZ, E. et al. Systematic Review and Meta-analysis of Cannabis Treatment for Chronic Pain. Pain Medicine, v. 10, n. 8, p. 1353–1368, nov. 2009.
NAEF, M. et al. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain, v. 105, n. 1, p. 79–88, set. 2003.
NOYES, R. et al. Analgesic Effect of Delta-9-Tetrahydrocannabinol. The Journal of Clinical Pharmacology, v. 15, n. 2-3, p. 139–143, 3 fev. 1975a.
NOYES, R. et al. The analgesic properties of delta-9-tetrahydrocannabinol and codeine. Clinical Pharmacology & Therapeutics, v. 18, n. 1, p. 84–89, jul. 1975b.
PETZKE, F. et al. Cannabis-Based Medicines and Medical Cannabis for Chronic Neuropathic Pain. CNS Drugs, 21 nov. 2021.
PHILLIPS, T. J. C. et al. Pharmacological Treatment of Painful HIV-Associated Sensory Neuropathy: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. PLoS ONE, v. 5, n. 12, p. e14433, 28 dez. 2010.
SKRABEK, R. Q. et al. Nabilone for the Treatment of Pain in Fibromyalgia. The Journal of Pain, v. 9, n. 2, p. 164–173, fev. 2008.
SVENDSEN, K. B.; JENSEN, T. S.; BACH, F. W. Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial. BMJ, v. 329, n. 7460, p. 253, 16 jul. 2004.
